wedbush view report season unfold decidedli uniqu
environ pandem chang mani facet daili life
commerci biotech coverag specif see limit impact
result howev look ahead beyond key question address
includ long lockdown persist potenti suppli chain insurance/
reimburs disrupt clinic trial site begin resum
recruit backdrop make chang current
outlook outperform-r neutral-r
target drop target move
move remain unchang
target move
result check anticip meaning
headwind ultomiri less frequent dose could prove
even relev reduc infus burden rais
soliris/ultomiri estim fall consensu
outperform new target posit commerci front
data still come manag continu execut deal
strengthen balanc sheet daiichi collabor see good
move current environ recent check-in manag
indic meaning impact relat disrupt continu
close monitor situat look addit updat regard data
readout time addit cohort prophylact steroid
outperform new target solid start launch result
unlik move needl nurtec launch kick
impact like limit nevertheless earli script data appear
encourag upcom troriluzol ocd alzheim data remain track
late extend vazegep launch time
year updat share count target move
outperform target look addit financi clariti
follow restructur chang estim follow last week
restructur announc link note look call
neutral new target anticip top-lin strength await
aducanumab clariti look earn report better understand
aducanumab time strategi potenti impact dian-tu studi
link lower tecfidera spinraza estim howev
slight share count adjust partial discount period laps
target increas
neutral target focu remain inbrija dynam anticip
limit impact print bigger issu contend
restructur effort affect inbrija demand chang
estim
wedbush secur seek busi compani cover
research report thu investor awar firm may
conflict interest could affect object report investor
consid report singl factor make invest decis
pleas see page report analyst certif import
wedbush view report season unfold decidedli uniqu environ
pandem chang mani facet daili life commerci biotech
coverag specif see limit impact result howev look ahead
beyond key question address includ long lockdown persist potenti suppli
chain insurance/reimburs disrupt clinic trial site begin resum
recruit backdrop make chang current outlook
outperform-r neutral-r
target drop target move move
remain unchang target move
note bmo market open market close tbd determin ws estim base
march djia largest single-day point drop histori fall point
nasdaq biotech index nbi mirror move single-day declin point
approxim declin howev sector ralli subsequ trade day
nbi sinc nearli back pre-crisi level figur
illustr nbi price move relat biotech/healthcar fund flow activ
rel sector see biotech experienc less disrupt compar broader
market nbi return versu last three month see figur
look close within healthcar subsector biotech perform past
three month led way compar group within healthcar space
note price
amidst backdrop recent market turbul note price-to-earnings multipl sector
actual risen sinc gap nbi price-to-earnings multipl
narrow see figur
figur sector valuat large- mid-cap commerci
note price
herein review company-specif outlook six commercial-stag compani within
coverag univers
outperform new target forese disrupt play role
perhap road report financi result figur
depict current estim rel current consensu estim prior
note product consensu obtain bloomberg total revenu ep estim thomson
note data point except ep
report period conduct numer check
private/publ compani clinic research organ trial coordinators/recruit
overal see limit potenti impact script data provid
symphonyhealth typic meaning product like soliri data partial
block reflect small proport overal report revenu exampl
report us soliri revenu symphonyhealth report integr
wac dollar captur rate acknowledg limit note soliri
integr wac dollar jan/feb y/i flat versu oct/nov period
mind rais soliris/ultomiri franchis estim
note remain current consensu
look ahead think global disrupt may becom appar headwind
convers ultomiri aid uptak lower strensiq kanuma
estim accordingli site may constrain conduct infus period
assumpt deriv fact product infus primarili clinic may
impact patient consid high-risk candid contract
diseas soliri discontinu therapi pnh ahu patient without
consequ given sever natur diseas think patient physician
motiv continu treatment trim estim
increas estim yield combin
soliris/ultomiri revenu ahead previous guid rang see
prior tabl chang
figur summar alxn current financi guidanc soliris/ultomiri
franchis estim move ahead guid rang behind consensu
combin metabol franchis revenu estim move
guid rang
figur current guidanc
note alexion financi guidanc base current foreign exchang rate net hedg activ
includ effect acquisit licens strateg agreement intang asset
impair litig charg chang fair valu conting consider gain loss relat
strateg equiti invest restructur relat activ outsid previous announc activ
may occur issuanc present updat guidanc includ financi impact
recent announc agreement acquir achillion close januari reconcili
non- financi guidanc avail www alexion com yoy growth use mid-point
guidanc rang
clinic trial side seen widespread disrupt clinic trial recruit see
previou note studi impact howev pivot studi complet
recruit stage nevertheless remain conserv push back
launch assumpt year model earliest potenti launch final
model adjust forward oper expens assumpt includ increas
 expens carri trajectori forward base recent spend trend
sg expens assumpt remain around revenu consist current
level manag guidanc
net chang yield new target previous deriv multipl
non-gaap ep estim discount back per year large-cap biotech peer
current trade multipl consensu earn risk clinic regulatori
outperform new target commerci progress matter focu
pipelin present anticip report result early-may base past
trend compani continu establish collabor strengthen balanc
sheet anticip investor focus potenti on-tim data readout recal
previous indic gene therapi data program third dose
cohort expect data prophylaxi steroid cohort over-the-counter
defici expect anticip updat potenti time readout
report compani better insight potenti disrupt due
part think fact single-dos administr benefici
howev follow-up monitor may impact certain site
mind figur illustr current estim versu consensu
base industri check convers anticip minim impact
commerci busi look broadli mepsevii may face greater
disrupt risk due fact infus product think crysvita abl maintain
trajectori total revenu estim remain unchang see
manag disclos crysvita transfer price khk also updat
model accordingli forward period decreas
mepsevii revenu estim unchang time
note product consensu obtain bloomberg total revenu ep estim thomson reuter
recal manag provid initi guidanc call crysvita revenu rang
shown addit compani previous guid
reduct net cash burn cours year recent announc daiichi
partnership gene therapi ad balanc sheet see note continu
see compani strong financi posit
figur current guidanc march
note crysvita revenu guidanc ultragenyx region exclud non-cash royalti revenu
eu exclud eu royalti revenu non-cash eu royalti revenu cash
equival available-for-sal invest decemb net cash use oper
plu capit expenditur base current busi exclud potenti genetx option exercis
rare gene therapi effort intern collaborators/partn remain entir
upsid current estim addit data unfold could provid
opportun get construct name stay consist valuat
methodolog net chang yield new target previous via sum-of-
part dcf analysi examin potenti cash flow mepsevii crysvita
discount back per year risk clinic regulatori commerci competit
outperform new target launch solid start progress unlik
move needl anticip report financi result earli may
nurtec market phase prevent data hand anticip
report somewhat unev product launch commenc latter part
period head event figur depict current estim
rel current consensu prior estim model nurtec
revenu
note product consensu obtain bloomberg total revenu ep estim thomson
recent script trend data depict first week launch strong start
rel abbv/agn ubrelvi lli reyvow figur contrast prescrib
count launch initi launch phase note nurtec launch
initi midst shutdown yet number rel consist
check-in kol indic slow-down clinic volum greater relianc
tele-medicin appoint possibl base trend leav
revenu estim unchang remain consensu
figur oral cgrp antagonist launch trend wrx count
continu use sum-of-part dcf analysi deriv target base potenti
cash flow nurtec discount back per year
compani previous guid initi phase studi vazegep potenti nda
file think like risk timelin given current clinic trial
dynam push estim potenti launch year also
updat share count follow offer deriv target previous
share risk clinic regulatori commerci competit
outperform target look addit clariti financ upcom
report expect report financi result earli may although specif date
announc compani announc workforc reduct earli april
gener annual expens save primarili reduct
sg activ see prior note anticip addit detail emerg notabl
cash runway extend
note product consensu obtain bloomberg total revenu ep estim thomson reuter
make chang estim point target remain via
sum-of-part dcf analysi incorpor potenti cash flow zulresso
discount back per year date manag note timelin remain track
previous describ await clariti addit
relat updat see prior note risk clinic regulatori commerci
neutral new target aducanumab file anticip top-lin
strength even amidst potenti headwind report financi result
market open term commerci busi script trend data ms
franchis suggest in-lin quarter rel consensu expect spinraza
note disrupt administr per compani commun via
curesma see link extent manifest quarter remain seen
tabl summar chang estim rel consensu prior
note product consensu obtain bloomberg total revenu ep estim thomson reuter
note data point except ep
ms franchis make minor adjust estim compani
updat major disrupt due report assum impact
result point symphonyhealth script data show dollar tecfidera
q/q appear rel unchang y/i basi given typic season trend
associ period moder us tecfidera revenu estim
q/q move ww tecfidera revenu estim consensu
recal report increas ms franchis us channel inventori
dynam limit regard tysabri inventori remain stabl
mind tysabri estim remain unchang although await clariti potenti
impact infus dynam likewis leav interferon estim
avonex/plegridi intact well spinraza base commentari around potenti
delay infus us lower estim model ww spinraza
revenu in-lin current consensu beyond revenu
chang also adjust sg expens assumpt
develop side continu await addit clariti aducanumab regulatori
submiss strategi recal manag previous indic file howev
point receiv notic submiss fda base check-in
variou public privat compani heard major delay come fda
although note roch risdiplam review extend three month follow
incorpor addit data bottom line pipelin still remain aducanumab
wake dian-tu studi result wonder result impact potenti
interpret continu believ addit studi necessari fulli
understand real benefit drug backdrop continu await addit
clariti assign credit aducanumab estim
standard practic manag provid financi guidanc updat
begin year mid-year updat slide provid current
financi guidanc framework although compani recent announc new collabor
sangamo incorpor up-front payment compani anticip
guidanc updat mid-year financi result report
note includ impact potenti acquisit larg busi develop transact
hard predict assum gener competit tecfidera
chang foreign exchang rate assum addit commerci expens relat
aducanumab stabl share count propos transact close expect capit
expenditur million million
continu use discount earn multipl vs large-cap peer deriv
price target net chang plu laps partial discount period
yield new target share previous share trade close
rang remain neutral rate stock risk clinic regulatori commerci
neutral target new quarter stori continu focu inbrija dynam
releas financi result focu stori remain unchang
await updat relat impact inbrija uptak symphonyhealth
data show inbrija trx dollar sequenti decreas
prior quarter see tracker note note current consensu revenu impli
q/q growth captur rate may come play wonder potenti
impact recent restructur inbrija sale ramp particularli prescrib count
wrx count appear plateau recent week
ampyra script data shown increas variabl recent month exampl
ampyra report dollar compar actual revenu
dollar versu prior quarter manag
current guid ampyra revenu rang note
typic impact season headwind
follow figur illustr current financi guidanc note
inbrija revenu estim lie lower end rang ampyra revenu
estim guid rang anticip continu
gener pressur cours year see figur
note oper expens guidanc non-gaap project exclud restructur cost share-
base compens fulli describ press releas date januari non-gaap
current estim inbrija ampyra remain unchang
respect estim in-lin rel current consensu pleas see tabl
detail breakdown chang valuat methodolog continu deriv
target share base weighted-averag price-to-earnings p/ sum-of-part analysi
note product consensu obtain bloomberg total revenu ep estim thomson reuter
risk attain price rate biotechnolog
risk achiev price target includ advers polit event better worse-than expect clinic data
under-perform outperform rate respect
laura chico certifi view express report accur reflect person opinion
directli indirectli receiv compens payment connect specif recommend view contain
report
outperform expect total return stock outperform rel median total return analyst analyst
team coverag univers next month
neutral expect total return stock perform in-lin median total return analyst analyst team
coverag univers next month
under-perform expect total return stock under-perform rel median total return analyst
analyst team coverag univers next month
invest rate base expect perform stock base anticip total return price target rel
stock analyst coverag univers analyst team coverag
april
april
distribut rate requir finra rule howev ws stock rate outperform neutral under-perform
close conform buy hold sell respect pleas note howev definit ws stock rate
rel basi
analyst respons prepar research report receiv compens base specif invest bank activ
analyst receiv compens base upon variou factor includ ws total revenu portion gener
ws invest bank activ
